IN BRIEF: Cellbxhealth eyes cost savings as revenue falls in 2025

Cellbxhealth PLC - Guildford, England-based liquid biopsy company, formerly called Angle PLC - Expects to report 2025 revenue of £1.4 million, down 51% from £2.9 million in 2024. The firm highlights it first expected revenue of £1.6 million for 2025, however a few sales contracts were deferred into the first quarter of 2026. Cash at December 31 was £7.3 million, down 30% from £10.4 million a year ago. Chief Executive Officer Peter Collins says: ‘The company remains on track with the execution of its organisational restructure and delivery of associated cost-saving measures. With management focused on refining the company’s business strategy, securing funding and implementing the restructure during the fourth quarter of 2025, some sales contracts, with an aggregate value of approximately £200,000, were deferred into the first quarter of 2026.’ The company will publish 2025 results in June.

Current stock price: 0.93 pence each, down 7.1% on Friday afternoon in London

12-month change: down 92%

Copyright 2026 Alliance News Ltd. All Rights Reserved.